Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer
AbstractThe growing knowledge on the mechanisms of gene silencing and gene regulation by non-coding RNAs (ncRNA), mainly small interfering RNA (siRNA) and microRNA (miRNA), is providing a significant boost to the development of new therapeutic strategies for the treatment of cancer. However, the design of RNA-based therapeutics is hampered by biopharmaceutical issues, thus requiring the use of suitable delivery strategies. In this regards, lipid nanovectors have been successfully investigated to deliver RNA in different forms of cancer. Compared to other biomaterials, lipids offer advantages such as biocompatibility, biodegradability, easy production, low cost, limited toxicity and immunogenicity. The possibility to formulate these materials in the form of nanovectors allows overcoming biopharmaceutical issues associated to the therapeutic use of RNA, with the possibility to target tumors. This review takes stock of the main lipid nanovectors proposed to deliver ncRNA. For each considered delivery strategy, the rational design and the most meaningful in vitro and in vivo results are reported and discussed. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Campani, V.; Salzano, G.; Lusa, S.; De Rosa, G. Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer. Nanomaterials 2016, 6, 131.
Campani V, Salzano G, Lusa S, De Rosa G. Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer. Nanomaterials. 2016; 6(7):131.Chicago/Turabian Style
Campani, Virginia; Salzano, Giuseppina; Lusa, Sara; De Rosa, Giuseppe. 2016. "Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer." Nanomaterials 6, no. 7: 131.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.